ElizabethJMcFarlandMD

Pediatric Infectious Disease • Aurora, CO

Professor, Pediatrics, University of Colorado School of Medicine

Join to view full profile

Dr. McFarland is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. McFarland's full profile

Already have an account?

Office
13123 E 16th Ave
Aurora, CO 80045
Phone+1 720-777-1234

Education & Training

University of ColoradoFellowship, Pediatric Infectious Diseases, 1992
University of ColoradoResidency, Pediatrics, 1985 - 1988
Duke University School of MedicineClass of 1985

Certifications & Licensure

CO State Medical License 1987 - 2025
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Infectious Diseases

Clinical Trials

Effects of Home Visits on Medication Adherence in Children and Youth With HIV
Unknown status
Not Applicable
Safety and Tolerability of a Therapeutic DNA Dendritic Cell Vaccine in HIV-Infected Children, Adolescents, and Young Adults
Withdrawn
Phase 1, Phase 2
IMPAACT 1077HS: Examining Benefits of HAART Continuation in Postpartum Women Start of enrollment: 2010 Jan 01
Completed
Phase 4
Surveillance Monitoring for ART Toxicities Study in HIV Uninfected Children Born to HIV Infected Women Start of enrollment: 2007 Mar 01
Recruiting
Connect to Protect (C2P): Building a Community-Based Infrastructure for HIV Prevention Start of enrollment: 2011 Nov 01
Completed
Not Applicable
An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis Use Among 15 to 17 Year Old Young Men Who Have Sex With Men (YMSM) Start of enrollment: 2013 Mar 01
Completed
Phase 2
Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Participants Start of enrollment: 2013 Aug 26
Terminated
Phase 2, Phase 3
Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV Start of enrollment: 2014 Jan 16
Recruiting
Phase 2, Phase 3
Adolescent Master Protocol for Participants 18 Years of Age and Older (AMP Up) Start of enrollment: 2014 Apr 01
Recruiting
Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children Start of enrollment: 2014 Sep 01
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

44 citations
Live-Attenuated Respiratory Syncytial Virus Vaccine Candidate With Deletion of RNA Synthesis Regulatory Protein M2-2 is Highly Immunogenic in Children.
Elizabeth J. McFarland, Ruth A. Karron, Petronella Muresan, Coleen K. Cunningham, Megan Valentine
The Journal of Infectious Diseases. 2018-04-11
39 citations
Live Respiratory Syncytial Virus (RSV) Vaccine Candidate Containing Stabilized Temperature-Sensitivity Mutations Is Highly Attenuated in RSV-Seronegative Infants and C...
Ursula J. Buchholz, Coleen K. Cunningham, Petronella Muresan, Devasena Gnanashanmugam, Paul A. Sato
The Journal of Infectious Diseases. 2018-04-11
25 citations
Live Respiratory Syncytial Virus Attenuated by M2-2 Deletion and Stabilized Temperature Sensitivity Mutation 1030s Is a Promising Vaccine Candidate in Children.
Elizabeth J. McFarland, Ruth A. Karron, Petronella Muresan, Coleen K. Cunningham, Jennifer Libous
The Journal of Infectious Diseases. 2020-02-03

Journal Articles

Development and Application of a Multiplex Assay for the Simultaneous Measurement of Antibody Responses Elicited by Common Childhood Vaccines
Elizabeth J McFarland, Coleen K Cunningham, William Borkowsky, Sallie R Permar, ScienceDirect